Quality of life, fatigue and markers in sarcoidosis: A section from Turkey
##plugins.themes.themeTen.article.main##
Keywords
Fatigue, sarcoidosis, health-related quality of life, age, lung, additional organ involvement
Abstract
Background and aim: Sarcoidosis can affect every organ with varying frequency based on ethnicity, gender and age. We aimed to evaluate the health-related quality of life (HRQoL) and fatigue levels of our sarcoidosis patients. However, our second aim is to determine whether patient or disease markers correlate with quality of life assessment questionnaires.
Materials and Methods: Pulmonary sarcoidosis patients who were followed up in the chest diseases outpatient clinic of our hospital were included in this prospective study. In the follow-up of 2023, routine blood tests, angiotensin-converting enzyme (ACE), posteroanterior lung (thorax computed tomography in patients with parenchymal involvement) were requested from the patients. Participants were asked to fill out the short-form 36-item questionnaire (SF-36), fatigue assessment scale (FAS) and fatigue severity scale (FSS) under the control of the outpatient clinic.
Results: A total of 189 patients, 139 (73.5%) female and 50 (26.5%) male, diagnosed with Sarcoidosis were included. The mean age of our patients was 53.1±13.6. ACE (IU/L) 68.5±44.5. Of the patients we followed up for pulmonary sarcoidosis, 111 (58.7%) had single organ involvement and 78 (41.3%) had additional organ involvement. FAS; It was high in 103 (64.3%) patients and 29 (15.3%) were very tired. FSS value was 4.45±0.7 (3-5.88). All SF-36 parameters were lower than expected; MH and SF was minimally lower, PF, RP, BP, GH, RE and VT were significantly lower. SF-36 scores were found to be lower in the women and additional organ involvement participating.
Conclusion: We found a significant decrease in HRQoL and an increase in fatigue scores of our patients. These changes were more pronounced in women participating in the study than in men. In addition, the involvement of additional organs with the lung negatively affected the quality of life.
References
2. Arkema EV, Grunewald J, Kullberg S, Eklund A, Askling J. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J. 2016 Dec;48(6):1690-99.
3. Musellim B, Kumbasar OO, Ongen G, et al. Epidemiological features of Turkish patients with sarcoidosis. Respir Med 2009;103(6):907-12.
4. Caplan A, Rosenbach M, Imadojemu S. Cutaneous Sarcoidosis. Semin. Respir. Crit. Care Med. 2020;41(5):689–99.
5. Bodaghi B, Touitou V, Fardeau C, Chapelon C, LeHoang P. Ocular sarcoidosis. Presse Med. 2012 Jun;41(6 Pt 2):e349-54.
6. Mañá J, Rubio-Rivas M, Villalba N, et al. Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: Cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain. Medicine (Baltimore). 2017 Jul;96(29):e7595.
7. Valeyre D, Bernaudin JF, Jeny F, et al. Pulmonary Sarcoidosis. Clin. Chest Med. 2015;36(4):631-41.
8. Nardi A, Brillet PY, Letoumelin P, et al. Stage IV Sarcoidosis: Comparison of Survival with the General Population and Causes of Death. Eur. Respir. J. 2011;38(6):1368–73.
9. Drent M, Strookappe B, Hoitsma E, De Vries J. Consequences of Sarcoidosis. Clin Chest Med. 2015 Dec;36(4):727-37.
10. Michielsen HJ, Drent M, Peros-Golubicic T, De Vries J. Fatigue is associated with quality of life in sarcoidosis patients. Chest. 2006 Oct;130(4):989-94.
11. Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2020;201(8):e26–e51.
12. Moor CC, Obi ON, Kahlmann V, Buschulte K, Wijsenbeek MS. Quality of life in sarcoidosis. J Autoimmun. 2023 Oct 7:103123.
13. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. Health-related quality of life of persons with sarcoidosis. Chest. 2004 Mar;125(3):997-1004.
14. Baughman RP, Barriuso R, Beyer K, et al. Sarcoidosis: patient treatment priorities. ERJ Open Res. 2018 Dec 21;4(4):00141-2018.
15. Judson MA, Spagnolo P, Stanfel R, et al. Living with sarcoidosis: Virtual roundtable dialogue with patients and healthcare professionals. Respir Med. 2023 Apr-May;210:107174.
16. Baughman RP, Drent M, Culver DA, et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012 Oct;29(2):90-8.
17. Harper LJ, Gerke AK, Wang XF, et al. Income and Other Contributors to Poor Outcomes in U.S. Patients with Sarcoidosis. Am J Respir Crit Care Med. 2020 Apr 15;201(8):955-64.
18. Hendriks C, Drent M, Elfferich M, De Vries J. The Fatigue Assessment Scale: quality and availability in sarcoidosis and other diseases. Curr Opin Pulm Med. 2018 Sep;24(5):495-503.
19. Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J. 2012 Jul;40(1):255-63.
20. Caballero T, Prior N. Burden of Illness and Quality-of-Life Measures in Angioedema Conditions. Immunol Allergy Clin North Am. 2017 Aug;37(3):597-616.
21. Kocyigit H, Aydemir O, Fisek G, Olmez N, Memis A. Validity and reliability of the Turkish version of Short Form 36: a study of patients with rheumatoid disorder. Turkish J Drugs Therap. 1999;12(2):102-6.
22. Marcellis RG, Lenssen A, Elfferich M, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 2011;38(3):628-634.
23. Armutlu K, Korkmaz NC, Keser I, et al. The validity and reliability of the Fatigue Severity Scale in Turkish multiple sclerosis patients. Int J Rehabil Res. 2007;30(1):81-85.
24. Saketkoo LA, Russell AM, Jensen K, et al. Health-related quality of life (HRQoL) in sarcoidosis: diagnosis, management, and health outcomes. Diagnostics. 2021;11(6):1089.
25. Vis R, van de Garde EM, Meek B, Korenromp IH, Grutters JC. Randomised, placebo-controlled trial of dexamethasone for quality of life in pulmonary sarcoidosis. Respir Med. 2020;165:105936.
26. De Vries J, Drent M. Quality of life and health status in sarcoidosis: a review of the literature. Clin Chest Med. 2008;29(3):525-532.
27. Jastrzębski D, Ziora D, Lubecki M, et al. Fatigue in sarcoidosis and exercise tolerance, dyspnea, and quality of life. Lung Cancer. 2015;31-36.
28. Harper LJ, Gerke AK, Wang XF, et al. Income and other contributors to poor outcomes in US patients with sarcoidosis. Am J Respir Crit Care Med. 2020;201(8):955-964.
29. De Vries J, Van Heck GL, Drent M. Gender differences in sarcoidosis: symptoms, quality of life, and medical consumption. Women Health. 2000;30(2):99-114.
30. Bourbonnais JM, Samavati L. Effect of gender on health-related quality of life in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(2):96-102.
31. Frye BC, Potasso L, Farin-Glattacker E, Birring S, Müller-Quernheim J, Schupp JC. FEV1 and BMI influence King's Sarcoidosis Questionnaire score in sarcoidosis patients. BMC Pulm Med. 2021;21:395.
32. Wirnsberger RM, de Vries J, Breteler MH, Van Heck GL, Wouters EFM, Drent M. Evaluation of quality of life in sarcoidosis patients. Respir Med. 1998;92(5):750-756.
33. Mihailović-Vučinić V, Gvozdenović B, Stjepanović M, et al. Administering the Sarcoidosis Health Questionnaire to sarcoidosis patients in Serbia. J Bras Pneumol. 2016;42(2):99-105.
34. Hinz A, Brähler E, Möde R, Wirtz H, Bosse-Henck A. Anxiety and depression in sarcoidosis: the influence of age, gender, affected organs, concomitant diseases, and dyspnea. Sarcoidosis Vasc Diffuse Lung Dis. 2012;9(2):139-146.
35. De Vries J, Drent M. Relationship between perceived stress and sarcoidosis in a Dutch patient population. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:57-63.
36. De Kleijn WP, De Vries J, Lower EE, et al. Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med. 2009;15(5):499-506.
37. Bloem AE, Mostard RL, Stoot N, et al. Severe fatigue is highly prevalent in patients with IPF or sarcoidosis. J Clin Med. 2020;9(4):1178.
##plugins.themes.themeTen.article.sidebar##
##plugins.themes.themeTen.article.details##
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
